169 related articles for article (PubMed ID: 19156501)
1. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
2. Cast nephropathy in a case of Waldenström's macroglobulinemia.
Isaac J; Herrera GA
Nephron; 2002 Jul; 91(3):512-5. PubMed ID: 12119489
[TBL] [Abstract][Full Text] [Related]
3. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
[TBL] [Abstract][Full Text] [Related]
4. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
7. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of Waldenström's macroglobulinemia.
Johnson SA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850
[TBL] [Abstract][Full Text] [Related]
9. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
11. Recovery of kidney function by rituximab-based therapy in a patient with Waldenström's macroglobulinemia-related nephropathy presenting cast nephropathy and interstitial lymphocytic infiltration.
Miwa M; Sakao Y; Ishigaki S; Ono M; Fujikura T; Yasuda H; Suzuki H; Kato A; Nagata Y; Shigeno K; Nakamura S; Ohnishi K; Fujigaki Y
Intern Med; 2012; 51(13):1725-30. PubMed ID: 22790134
[TBL] [Abstract][Full Text] [Related]
12. Renal involvement in Waldenström's macroglobulinemia: case report and review of literature.
Salviani C; Guido G; Serriello I; Giannakakis K; Rocca AR
Ren Fail; 2014 Feb; 36(1):114-8. PubMed ID: 24059636
[TBL] [Abstract][Full Text] [Related]
13. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
Noronha V; Fynan TM; Duffy T
J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
[No Abstract] [Full Text] [Related]
14. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
15. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
16. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
Treon SP; Hunter Z; Barnagan AR
Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
[TBL] [Abstract][Full Text] [Related]
17. Membranoproliferative glomerulonephritis complicating Waldenström's macroglobulinemia.
Kratochvil D; Amann K; Bruck H; Büttner M
BMC Nephrol; 2012 Dec; 13():172. PubMed ID: 23259458
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
19. Waldenström's macroglobulinemia.
Dimopoulos MA; Galani E; Matsouka C
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1351-66. PubMed ID: 10626154
[TBL] [Abstract][Full Text] [Related]
20. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.
Weide R; Heymanns J; Köppler H
Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
